TY - JOUR
T1 - Acceptability of a novel suicide prevention psychological therapy for people who experience non-affective psychosis
AU - Harris, Kamelia
AU - Gooding, Patricia
AU - Awenat, Yvonne
AU - Haddock, Gillian
AU - Cook, Leanne
AU - Huggett, Charlotte
AU - Jones, Steven
AU - Lobban, Fiona
AU - Peeney, Ellen
AU - Pratt, Daniel
AU - Peters, Sarah
PY - 2023/2/13
Y1 - 2023/2/13
N2 - Objectives: Suicide is a leading cause of death worldwide. People experiencing psychosis are at increased risk of death by suicide. Talking therapies can alleviate suicidal thoughts, plans, and attempts. Therapies need to also be acceptable to recipients. The aim of this study was to investigate the views on a psychological therapy for people experiencing psychosis and suicidality using the Theoretical Framework of Acceptability.Design: Qualitative interview study.Methods: Participants were recruited from a randomised controlled trial comparing suicide prevention psychological therapy with treatment as usual. Individuals had a diagnosis of non- affective psychosis and experience of suicidal thoughts, plans, and/or attempts. To assess acceptability of the therapy, semi-structured interviews were conducted with 20 participants randomised to receive therapy. Data were deductively analysed using an adaptation of the Theoretical Framework of Acceptability.Results: Interviews (Mean = 45 minutes) were conducted, and audio recorded with 21 participants. Data were organised into six themes: 1. Affective attitude, 2. Burden, 3. Alliance, 4. Intervention coherence, 5. Perceived effectiveness, and 6. Self-efficacy. There was no evidence of issues relating to domains of ethicality and opportunity costs associated with receiving therapy.Conclusions: Talking about suicide was difficult and, at times, distressing, but it was perceived to be useful for understanding experiences. To be acceptable, it is important for therapists to ensure that clients’ understanding of therapy aligns with expectations of effectiveness and to invest in building strong therapeutic alliances. Future research will benefit from examining therapists’ experiences of delivering therapy by different modes (e.g., online, telephone).
AB - Objectives: Suicide is a leading cause of death worldwide. People experiencing psychosis are at increased risk of death by suicide. Talking therapies can alleviate suicidal thoughts, plans, and attempts. Therapies need to also be acceptable to recipients. The aim of this study was to investigate the views on a psychological therapy for people experiencing psychosis and suicidality using the Theoretical Framework of Acceptability.Design: Qualitative interview study.Methods: Participants were recruited from a randomised controlled trial comparing suicide prevention psychological therapy with treatment as usual. Individuals had a diagnosis of non- affective psychosis and experience of suicidal thoughts, plans, and/or attempts. To assess acceptability of the therapy, semi-structured interviews were conducted with 20 participants randomised to receive therapy. Data were deductively analysed using an adaptation of the Theoretical Framework of Acceptability.Results: Interviews (Mean = 45 minutes) were conducted, and audio recorded with 21 participants. Data were organised into six themes: 1. Affective attitude, 2. Burden, 3. Alliance, 4. Intervention coherence, 5. Perceived effectiveness, and 6. Self-efficacy. There was no evidence of issues relating to domains of ethicality and opportunity costs associated with receiving therapy.Conclusions: Talking about suicide was difficult and, at times, distressing, but it was perceived to be useful for understanding experiences. To be acceptable, it is important for therapists to ensure that clients’ understanding of therapy aligns with expectations of effectiveness and to invest in building strong therapeutic alliances. Future research will benefit from examining therapists’ experiences of delivering therapy by different modes (e.g., online, telephone).
M3 - Article
JO - Psychology & Psychotherapy
JF - Psychology & Psychotherapy
SN - 1476-0835
ER -